234 related articles for article (PubMed ID: 37601851)
1. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.
O'Neill C; van de Donk NWCJ
EJHaem; 2023 Aug; 4(3):811-822. PubMed ID: 37601851
[TBL] [Abstract][Full Text] [Related]
2. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
Hosny M; Verkleij CPM; van der Schans J; Frerichs KA; Mutis T; Zweegman S; van de Donk NWCJ
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640611
[TBL] [Abstract][Full Text] [Related]
3. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
4. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
6. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
8. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
9. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni L; Sidana S
J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
[TBL] [Abstract][Full Text] [Related]
10. Targeting GPRC5D in multiple myeloma.
Elemian S; Al Hadidi S
Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
[TBL] [Abstract][Full Text] [Related]
11. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
12. T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.
Verkleij CPM; O'Neill CA; Broekmans MEC; Frerichs KA; Bruins WSC; Duetz C; Kruyswijk S; Baglio SR; Skerget S; Montes de Oca R; Zweegman S; Verona RI; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38687588
[TBL] [Abstract][Full Text] [Related]
13. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Hammons L; Szabo A; Janardan A; Bhatlapenumarthi V; Annyapu E; Dhakal B; Al Hadidi S; Radhakrishnan SV; Narra R; Bhutani D; Thanendrarajan S; Janz S; Zangari M; Lentzsch S; Van Rhee F; Crescencio JCR; D'Souza A; Chakraborty R; Mohan M; Schinke C
Haematologica; 2024 Mar; 109(3):906-914. PubMed ID: 37646658
[TBL] [Abstract][Full Text] [Related]
14. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Mazahreh F; Mazahreh L; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
Blood Adv; 2023 Jul; 7(13):3069-3074. PubMed ID: 36857755
[TBL] [Abstract][Full Text] [Related]
15. T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ; Zweegman S
Lancet; 2023 Jul; 402(10396):142-158. PubMed ID: 37271153
[TBL] [Abstract][Full Text] [Related]
16. A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.
Tomita U; Ishimoto Y; Ri M; Kawase Y; Hizukuri Y; Maru C; Nanai K; Nakamura R; Nakayama M; Oguchi-Oshima K; Sumi H; Ohtsuka T; Iida S; Agatsuma T
Sci Rep; 2024 Mar; 14(1):5135. PubMed ID: 38429446
[TBL] [Abstract][Full Text] [Related]
17. Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.
Huo J; Huang Y; Zheng Z; Tay XN; Mahfut FB; Zhang W; Lam KP; Yang Y; Xu S
Antib Ther; 2022 Apr; 5(2):138-149. PubMed ID: 35774245
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibodies in multiple myeloma treatment: A journey in progress.
Cho SF; Yeh TJ; Anderson KC; Tai YT
Front Oncol; 2022; 12():1032775. PubMed ID: 36330495
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
Parrondo RD; Ailawadhi S; Cerchione C
Front Oncol; 2024; 14():1394048. PubMed ID: 38660139
[TBL] [Abstract][Full Text] [Related]
20. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]